(Q62030895)
Statements
An Open-label, Multicenter, Phase Ib Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects Aged 2 to 17 Years With Atopic Dermatitis (English)
0 references
7 December 2018
0 references
May 2019
0 references
36
0 references
2 year
0 references
17 year
0 references